Logo image of KNSA

KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Overview

USA - NASDAQ:KNSA - GB00BRXB0C07 - Common Stock

35.42 USD
-0.5 (-1.39%)
Last: 9/19/2025, 8:25:03 PM
35.42 USD
0 (0%)
After Hours: 9/19/2025, 8:25:03 PM

KNSA Key Statistics, Chart & Performance

Key Statistics
52 Week High37.34
52 Week Low17.82
Market Cap2.62B
Shares74.11M
Float41.81M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.04
PE885.5
Fwd PE21.47
Earnings (Next)10-21 2025-10-21
IPO05-24 2018-05-24
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


KNSA short term performance overview.The bars show the price performance of KNSA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40 50

KNSA long term performance overview.The bars show the price performance of KNSA in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of KNSA is 35.42 USD. In the past month the price increased by 5.48%. In the past year, price increased by 38.14%.

KINIKSA PHARMACEUTICALS INTE / KNSA Daily stock chart

KNSA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.01 393.01B
AMGN AMGEN INC 13.09 153.65B
GILD GILEAD SCIENCES INC 14.74 141.56B
VRTX VERTEX PHARMACEUTICALS INC 22.62 98.23B
REGN REGENERON PHARMACEUTICALS 12.97 62.75B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.45B
ARGX ARGENX SE - ADR 79.48 45.09B
ONC BEONE MEDICINES LTD-ADR 5.84 39.75B
INSM INSMED INC N/A 30.60B
NTRA NATERA INC N/A 24.86B
BNTX BIONTECH SE-ADR N/A 23.13B
BIIB BIOGEN INC 8.9 20.89B

About KNSA

Company Profile

KNSA logo image Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

Company Info

KINIKSA PHARMACEUTICALS INTE

23 Old Bond Street, Floor 3

London HM11 GB

CEO: Sanj K. Patel

Employees: 315

KNSA Company Website

KINIKSA PHARMACEUTICALS INTE / KNSA FAQ

What is the stock price of KINIKSA PHARMACEUTICALS INTE today?

The current stock price of KNSA is 35.42 USD. The price decreased by -1.39% in the last trading session.


What is the ticker symbol for KINIKSA PHARMACEUTICALS INTE stock?

The exchange symbol of KINIKSA PHARMACEUTICALS INTE is KNSA and it is listed on the Nasdaq exchange.


On which exchange is KNSA stock listed?

KNSA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for KINIKSA PHARMACEUTICALS INTE stock?

12 analysts have analysed KNSA and the average price target is 45.7 USD. This implies a price increase of 29.01% is expected in the next year compared to the current price of 35.42. Check the KINIKSA PHARMACEUTICALS INTE stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is KINIKSA PHARMACEUTICALS INTE worth?

KINIKSA PHARMACEUTICALS INTE (KNSA) has a market capitalization of 2.62B USD. This makes KNSA a Mid Cap stock.


How many employees does KINIKSA PHARMACEUTICALS INTE have?

KINIKSA PHARMACEUTICALS INTE (KNSA) currently has 315 employees.


What are the support and resistance levels for KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

KINIKSA PHARMACEUTICALS INTE (KNSA) has a support level at 35.41 and a resistance level at 37.11. Check the full technical report for a detailed analysis of KNSA support and resistance levels.


Is KINIKSA PHARMACEUTICALS INTE (KNSA) expected to grow?

The Revenue of KINIKSA PHARMACEUTICALS INTE (KNSA) is expected to grow by 34.22% in the next year. Check the estimates tab for more information on the KNSA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does KINIKSA PHARMACEUTICALS INTE (KNSA) stock pay dividends?

KNSA does not pay a dividend.


When does KINIKSA PHARMACEUTICALS INTE (KNSA) report earnings?

KINIKSA PHARMACEUTICALS INTE (KNSA) will report earnings on 2025-10-21.


What is the Price/Earnings (PE) ratio of KINIKSA PHARMACEUTICALS INTE (KNSA)?

The PE ratio for KINIKSA PHARMACEUTICALS INTE (KNSA) is 885.5. This is based on the reported non-GAAP earnings per share of 0.04 and the current share price of 35.42 USD. Check the full fundamental report for a full analysis of the valuation metrics for KNSA.


What is the Short Interest ratio of KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

The outstanding short interest for KINIKSA PHARMACEUTICALS INTE (KNSA) is 6.48% of its float. Check the ownership tab for more information on the KNSA short interest.


KNSA Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to KNSA. When comparing the yearly performance of all stocks, KNSA is one of the better performing stocks in the market, outperforming 84.84% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

KNSA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to KNSA. KNSA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KNSA Financial Highlights

Over the last trailing twelve months KNSA reported a non-GAAP Earnings per Share(EPS) of 0.04. The EPS increased by 125% compared to the year before.


Industry RankSector Rank
PM (TTM) 0.9%
ROA 0.72%
ROE 0.97%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%483.33%
Sales Q2Q%51.65%
EPS 1Y (TTM)125%
Revenue 1Y (TTM)56.18%

KNSA Forecast & Estimates

12 analysts have analysed KNSA and the average price target is 45.7 USD. This implies a price increase of 29.01% is expected in the next year compared to the current price of 35.42.

For the next year, analysts expect an EPS growth of 170.9% and a revenue growth 34.22% for KNSA


Analysts
Analysts86.67
Price Target45.7 (29.02%)
EPS Next Y170.9%
Revenue Next Year34.22%

KNSA Ownership

Ownership
Inst Owners94.65%
Ins Owners3.76%
Short Float %6.48%
Short Ratio4.82